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Objectives. We sought to form a consensus recommendation for
management of prosthetic valve thrombosis (PVT) from previous
case and uncontrolled reports from a consensus of international
specialists.
Background. PVT and thromboembolism relate to inadequate
anticoagulation and valve type and location. PVT is suspected by
history (dyspnea) and auscultation (muffled valve sounds or new
murmurs) and confirmed by Doppler echocardiography showing a
marked valve gradient.
Methods. A consensus conference was held to recommend
management of left-sided PVT.
Results. Transesophageal Doppler echocardiography is used to
visualize abnormal leaflet motion and the size, location and
mobility of thrombus. Thrombolysis is used for high risk surgical
candidates with left-sided PVT (New York Heart Association
functional class III or IV) because cerebral thromboembolism
may occur in 12% of patients. Duration of thrombolysis depends
on resolution of pressure gradients and valve areas to near
normal by Doppler echocardiography performed every few hours.
Lysis is stopped after 72 or 24 h if there is no hemodynamic
improvement (operation indicated). Heparin infusion with fre-
quent measurement of activated partial thromboplastin time
(aPTT) begins when aPTT is more than twice control levels and
can be converted to warfarin (international normalized ratio
[INR] 2.5 to 3.5) plus aspirin (81 to 100 mg/day). Patients in
functional class I or II have lower surgical mortality, and those
with large immobile thrombi on the prosthetic valve or left atrium
have responded to endogenous lysis with combined subcutaneous
heparin every 12 h (aPTT 55 to 80 s) plus warfarin (INR 2.5 to 3.5)
for 1 to 6 months. Operation is advised for nonresponders or
patients with mobile thrombi.
Conclusions. Thrombolysis, followed by heparin, warfarin and
aspirin, is advised for high risk surgical candidates with left-sided
PVT.
(J Am Coll Cardiol 1997;30:1521–6)
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Inadequate anticoagulation in patients with mechanical heart
valves can result in a significant incidence of thromboembo-
lism. The incidence of prosthetic valve thrombosis (PVT) and
total thromboembolism (thrombolism with permanent deficit
or transient ischemia) during warfarin (Coumadin) therapy is
dependent on valve type and location and especially adequacy
of anticoagulation and averages 0.2% and 1.8%/patient-year,
respectively (1). The incidence of PVT may be as high as 13%
in year 1 or 20% overall in patients with tricuspid valve
protheses and 0.2% to 6%/patient-year in those with aortic or
mitral valve prostheses (2,3). Operation has been the tradi-
tional treatment for PVT. However, reported operative mor-
tality rates range between 0% and 69%, largely depending on
clinical functional class (3–5). Fibrinolytic therapy is an alter-
native to surgical treatment (3,6–15) and is considered the
treatment of choice for tricuspid PVT (16,17). However,
because of the high risk of cerebral thromboembolism during
thrombolysis for left-sided PVT, its use is reserved for high risk
surgical candidates (4,18–23); the use of thrombolysis in low
risk patients remains controversial. A search of at least 200
published reports of left-sided prosthetic valve thrombolysis
showed an 82% initial success rate, an overall thromboembo-
lism rate of 12%, and a stroke rate of 5% to 10%, with 6%
death, 5% major bleeding episodes and 11% recurrent throm-
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bosis (3–6,9–15,18–35). The larger studies are summarized in
Table 1.
Thus, there is a need to define indications and management
guidelines for thrombolytic therapy with left-sided PVT on the
basis of benefit and risk of thrombolytic and antithrombotic
therapy that takes into account the functional class of the
patient, left ventricular function and overall operative risk.
Optimal antithrombotic treatment to prevent thromboembolic
complications also needs definition. Transesophageal Doppler
echocardiography (TEE) has recently been reported to be the
diagnostic technique of choice for selecting and monitoring
candidates for safe and efficacious thrombolytic treatment of
mitral PVT (9,11,12,25–28,36,37). Some investigators use cine-
fluoroscopy (14). A consensus conference was therefore con-
vened to formalize practical guidelines for the management of
left-sided aortic and mitral PVT.
Diagnosis of Left-Sided PVT
Clinical presentation of patients with left-sided PVT: defi-
nition of groups. Group 1 includes patients with clinically
silent PVT diagnosed by TEE performed for some other
clinical reason. Group 2 includes patients with PVT and stroke
or TIA or peripheral systemic embolism. Group 3 includes
patients with hemodynamic symptoms and evidence of valve
obstruction (most common). Group 4 includes patients with
both systemic embolism and hemodynamic evidence of valve
obstruction. Patients in Group 1 or 2 have usually mild
symptoms related to PVT (New York Heart Association
functional class I or II). They may have other causes of cardiac
symptoms, such as left ventricular dysfunction, tricuspid regur-
gitation or atrial fibrillation with uncontrolled ventricular rate.
Patients in Groups 3 and 4 are usually more symptomatic
(functional class III or IV, critically ill) (3,8,14).
Diagnostic approach and tests for PVT. Clinical evaluation
includes history for type, severity and duration of symptoms;
auscultation; electrocardiogram; and chest radiograph. Signs
and symptoms of infective endocarditis should be sought.
Previous adequacy of anticoagulation should be defined.
The auscultatory findings of muffled prosthetic valve sounds
or murmurs can be of great value; however, auscultation may
be unreliable if the obstruction is partial, as with a bileaflet
valve or in the presence of another normally functioning
prosthesis (15).
Cinefluoroscopy assesses restriction of leaflet motion and
opening and closing angles, complements TEE and is limited
to radiopaque disc or bileaflet valves (14,24).
TEE may visualize restricted prosthetic valve leaflet mo-
tion. It images thrombus on the atrial but rarely on ventricular
surface of mitral prosthetic valves (3). An eccentric and narrow
mitral inflow jet by color Doppler echocardiography raises
suspicion of partial valve obstruction.
Measurement of Doppler echocardiographic hemodynamic
variables is essential for assessment of obstructive PVT by
measurement of gradients and valve area (8,11,13,19,20). A
flow-dependent Doppler gradient is insufficient for diagnosis,
unless the gradient is very high. A Doppler gradient may
significantly overestimate the hemodynamic situation in the
aortic position, particularly with small prostheses and with St.
Jude valves (38). There is a significant variety of normal
gradient and area values even within the same valve type and
size (39). To avoid misinterpretation of patient or prosthesis
hemodynamic variables, most investigators now recommend
baseline postoperative/predischarge/Doppler measurements
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
CT 5 computed tomographic
INR 5 international normalized ratio
LA 5 left atrial
PVT 5 prosthetic valve thrombosis
rt-PA 5 recombinant tissue-type plasminogen activator
SK 5 streptokinase
TEE 5 transesophageal Doppler echocardiography
(echocardiographic)
TIA 5 transient ischemic attack
UK 5 urokinase













1988 (21) 58 62 23/39 11 14 6 4
1992 (3) 63 74 33/41* 11 11 9 2
1993 (14) 12 12 9/3† 0 0 0 0
1994 (8) 38 44 5/40‡ 0 0§ 5\ 0
1994 (12) 8 8 1/7 1 0 0 0
Total 179 200 71/130 23 (12%) 25 20 1 6 5 26
*Immediate efficacy better for aortic valve (AV) (85%) than for mitral valve (MV) (63%). †All St. Jude (bileaflet)
valves; diagnosis and follow-up primarily by cinefluoroscopy. ‡One episode involved both aortic and mitral valves, 43/45
bileaflet valves. §Patients could not afford reoperation. \Four of five patients presented with shock and one with
pulmonary edema; all five failed to respond to thrombolysis. Postop 5 postoperative; Pts 5 patients; ref 5 reference;
Reop 5 reoperation; TE 5 thromboembolism.
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(40,41). Increased gradients may be caused by other hemody-
namic factors unrelated to prosthetic valve malfunction, such
as tachycardia, residual subaortic septal hypertrophy or high
cardiac output, such as may be caused by anemia.
TEE is recognized by many as the technique of choice for
visualizing not just prosthetic valve leaflet motion abnormali-
ties (which may be more difficult in the aortic position) but also
for determining the etiology (38–41). Size, location and mo-
bility of the thrombus can be visualized. In addition, TEE can
detect thrombi in the body or appendage of the left atrium.
Monoplane TEE has a much lower diagnostic accuracy than
biplane or multiplane TEE. Fluoroscopy in the proper projec-
tion may be considered for initial screening of mechanical
bileaflet valve motion (3,14,24).
Laboratory studies. Current and previous prothrombin
times (measured as international normalized ratios [INRs])
may provide important clues to the diagnosis of PVT. In the
febrile patient, blood cultures should be drawn. A complete
blood count, including platelet count, activated partial throm-
boplastin time (aPTT) and fibrinogen and D-dimer levels
should be determined as baseline values for possible subse-
quent heparin or fibrinolytic therapy. Because the patient may
need urgent operation, additional baseline studies should be
obtained. In patients with stroke, TIAs or history of cerebral
events, magnetic resonance imaging or a computed tomo-
graphic (CT) of the brain can effectively differentiate between
hemorrhagic and ischemic stroke and also helps to rule out
nonvascular lesions. Absence of blood on early magnetic
resonance imaging or CT is important information supporting
the diagnosis of ischemic stroke in patients with a stroke
syndrome (42).
Indications for Thrombolysis
Thrombolytic treatment of left-sided PVT has been ac-
cepted for critically ill patients in functional class III or IV in
whom surgical intervention carries high risk or in patients with
contraindication to operation (18). The reasoning against
thrombolysis in patients in functional class I or II is based on
the relatively low surgical mortality in this group as opposed to
the embolic risk of 12% to 17% caused by thrombolysis
(3,15,18,43). Reports of thrombolytic treatment in 32 patients
presenting in functional class I or II show an 88% success rate,
3% (1 patient) major stroke rate and zero mortality (3,9,11,13–
15,26,27), whereas the lowest surgical mortality rate in a
similar group has been reported as 5%. The experience with
heparin treatment of nonobstructive PVT has been reported in
19 cases (9,27) with a 63% success rate, 2 cases of minor
cerebral embolism and 1 case (5%) of fatal stroke. An alter-
native approach used successfully by some investigators in
functional class I or II patients with a large amount of
thrombus takes advantage of the different antithrombotic
actions of heparin and warfarin and their enhancement of
longer term endogenous lysis. The use of subcutaneous hepa-
rin (every 12 h, aPTT 55 to 80 s) plus warfarin (INR 2.5 to 3.5)
for ;3 months usually dissolves moderate amounts of residual
thrombosis.
Patients with mitral or aortic PVT documented by TEE
with Doppler flow obstruction and functional class III or IV
symptoms should be treated with fibrinolysis if the surgical risk
is high and there is no contraindication. Surgical therapy is an
alternative for patients in functional class III or IV not at high
surgical risk. In addition, obstruction due to endocarditis with
abscess formation and usually very large thrombi with obstruc-
tion or mobile masses are indications for operation. The
benefit and risk of the many factors of the individual patient
must be balanced against the expertise and experience at each
center to arrive at a decision for thrombolysis or operation (4).
Nonobstructive PVT in patients presenting in functional
class I or II (Groups 1 and 2) may be treated with intravenous
heparin by continuous infusion for 48 h. If patients remain
hemodynamically stable and thrombus is not dissolved (not
unusual), intravenous infusion can be converted to subcutane-
ous injection (overlap infusion for 2 h after injection, average
dose from five studies is 17,000 U subcutaneously every 12 h)
(44) and combined with warfarin (INR 2.5 to 3.5) for 1 to 3
months on an outpatient basis to allow endogenous thrombol-
ysis. Combined warfarin and subcutaneous heparin are espe-
cially helpful for consistent antithrombotic therapy in the
patient with a variable INR. Initial experience suggests a very
low risk for bleeding. With complete or nearly complete
resolution of thrombus, the need for operation may be
avoided. Valve types (all may thrombose) or the suspected
duration of valve thrombosis does not influence the choice of,
or indications for, treatment (3,8,12,14,21).
Contraindications to Thrombolysis
Contraindications to thrombolysis are shown in Table 2.
Pregnancy is generally considered a relative contraindication.
However, when there is great danger to the patient, the
Table 2. Contraindications to Thrombolysis
Absolute contraindications
Active internal bleeding
History of hemorrhagic stroke
Recent cranial trauma or neoplasm
Blood pressure .200/120 mm Hg
Diabetic hemorrhagic retinopathy
Relative contraindications
Recent (within 10 days) gastrointestinal bleeding
Recent (within 10 days) puncture of noncompressible vessels
Recent (within 2 mo) nonhemorrhagic stroke
Infective endocarditis
Uncontrolled severe hypertension
Large thrombus in left atrium or on prosthesis
Recent (within 2 wk) major operation or trauma
Known bleeding diathesis
Previous exposure to streptokinase or APSAC (contraindication to reuse
any streptokinase-containing agent)
APSAC 5 anistreplase (anisoylated plasminogen streptokinase activator
complex).
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advantages and disadvantages of fibrinolysis should be consid-
ered. There have been at least four reported cases (3,15,29) in
which fibrinolysis was successfully used during pregnancy, with
no harm to the fetus.
Left-sided intracardiac thrombus has previously been con-
sidered a relative contraindication to thrombolysis. Patients
with large thrombotic material attached to the prosthetic valve
or in the left atrium are probably at increased risk of major
embolism and stroke when treated with thrombolytic therapy
(30). Although a few reports of successful thrombolysis of left
atrial (LA) clots have been published (43,45), a large LA
thrombus should be ruled out by TEE before the start of
thrombolytic treatment. Early postoperative (at least by the
tenth postoperative day) successful thrombolysis has also been
reported (27,34,43) with no contraindications in a small num-
ber of cases. However, adequate and prolonged anticoagula-
tion with heparin and then warfarin for 3 to 6 months for large,
nonobstructive thrombi will usually lead to dissolution by
endogenous thrombolysis, as seen by Doppler echocardio-
graphic follow-up of individual patients with valvular or LA
thrombi by the authors (M.L., V.F., J.S., J.C.).
Thrombolytic Agent, Dosage Duration and
Monitoring of Treatment
Streptokinase (SK) and urokinase (UK) have been the most
commonly used fibrinolytic agents; there was no statistically
significant difference in their success rates (18). Patients with
known allergy to SK or those who have been exposed previ-
ously to SK should be given UK (43). The recommended
dosage of SK is a 250,000-U bolus given in 30 min, followed by
an infusion of 100,000 U/h. UK is given as in pulmonary
embolism: 4,400 U/kg per h (43). The use of recombinant
tissue-type plasminogen activator (rt-PA) has also been re-
ported in doses used in the treatment of pulmonary embolism,
but it is more costly, and no advantage of rt-PA for valve
thrombosis has been demonstrated over SK or UK. Indeed,
rt-PA may increase risk; two fatal strokes and one additional
death occurred in 21 patients treated for PVT with rt-PA
(3,12,26,30,31,46). However, superior results of rt-PA com-
pared with those for SK in patients with acute stroke are
discussed later.
Duration of administration of thrombolytic agents depends
on the achievement of an improved hemodynamic effect or the
disappearance of thrombus. In obstructive PVT, Doppler
echocardiographic (performed every 2 to 3 h) is recommended
for hemodynamic monitoring. Thrombolytic infusion should be
stopped when values of pressure gradient and valve area return
to normal or near normal. If there is no normal baseline value
for a given patient and the result is equivocal, repeat TEE is
recommended. In nonobstructive cases, TEE is the only tech-
nique that is useful for monitoring treatment. TEE should be
performed at 24 h and if thrombus is still present, should be
repeated at 48 and at 72 h if necessary. Duration of thrombo-
lytic treatment has varied between 2 and 120 h (13,21). The
administration of lytic agent should be stopped if there is no
hemodynamic improvement at 24 h or after 72 h, even without
complete hemodynamic recovery. If D-dimer and aPTT do not
increase, and fibrinogen does not decrease at 24 h of lytic
treatment (failure to document a lytic state), the infusion can
be discontinued. If SK was used, UK may be tried because
antibodies to SK may have prevented its action.
In case of unsuccessful thrombolysis, operation is indicated
and can be performed 24 h after the discontinuation of the
infusion (34) or 2 h after fibrinolytic activity has been neutral-
ized by protease inhibitors (15).
Management of Complications
Low rates of thromboembolism are reported for lysis of
bileaflet valves (Table 1).
Peripheral embolism. Thrombolytic and then antithrom-
botic therapy should be continued, irrespective of the hemo-
dynamic results, to dissolve the peripheral embolus. Severe
peripheral embolism with persistent symptoms despite lysis
should be treated by embolectomy.
Cerebral embolism. The efficacy of early thrombolytic
treatment of acute stroke for improvement at 3 months has
been established for patients not receiving anticoagulant ther-
apy, with no bleeding and no or only minor early signs of
infarction on the initial CT scan. They are treated with
short-term (1 h) rt-PA therapy within 3 h of onset (47).
Treatment ,6 h from onset targeted another specific group
with moderate to severe hemispheric stroke (48–50). Two
large randomized trials of intravenous SK treating most pa-
tients .3 h after onset of stroke were stopped early because of
unacceptable rates of intracranial hemorrhage (51,52). An-
other trial showed no significant benefit for combined fatality
and severe disability at 6 months (53).
Thrombolytic treatment should be discontinued if neuro-
logic symptoms of stroke develop. A CT scan of the brain
should be urgently obtained to rule out hemorrhage. If the
stroke is nonhemorrhagic, anticoagulant treatment may be
administered. If the second CT scan performed 36 to 48 h after
the stroke still rules out brain hemorrhage, operation may be
performed 72 h after the stroke.
Bleeding. Minor bleeding is anticipated at puncture or
incision sites. If bleeding occurs, local pressure should be
applied to control it. Severe internal bleeding involving intra-
cranial, gastrointestinal, genitourinary, retroperitoneal or pre-
vious puncture sites can occur and result in fatalities. If major
bleeding occurs, the thrombolytic infusion should be immedi-
ately terminated. If necessary, bleeding can be reversed with
fresh-frozen plasma or more rapidly with prothrombin com-
plex concentrate containing Factor VII and blood loss man-
aged with appropriate replacement therapy.
Anticoagulant treatment. During thrombolytic treatment,
adjuvant anticoagulant therapy is not recommended. Admin-
istration of warfarin should be discontinued during thrombol-
ysis. There is usually no need to reverse its effect by vitamin K.
At the end of thrombolytic therapy, treatment with heparin by
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continuous infusion is recommended to prevent recurrent
thrombosis. Heparin treatment without a loading dose should
begin when the aPTT has decreased to less than twice the
normal control (or baseline) value. Heparin dosage is
considered adequate if the aPTT is 1.5 to 2 times normal (55
to 80 s). The average dosage to achieve this effect is 20,000 to
40,000 U/24 h. The initial heparin dosage is usually 1,300 U/h
(54). Because of rapidly changing levels of fibrinogen and
heparin binding proteins over the first 24 to 48 h after stopping
thrombolysis, the aPTT should be checked four times every 6 h
and three times every 8 h, then daily. Conversion to oral
anticoagulant treatment is performed in the usual manner, by
starting warfarin simultaneously with heparin (55).
Management of patients after successful thrombolytic
treatment. Anticoagulation is targeted to an INR of 2.5 to 3.5
according to the standard recommendations (56), and the
addition of aspirin (81 to 100 mg daily) is strongly recom-
mended (57). Close follow-up of anticoagulant control is
necessary, along with clinical assessment and Doppler echo-
cardiography on an individual basis. Doppler echocardiogra-
phy should be performed at least monthly during the first 6
months, then every 6 months.
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